Computed tomography (CT) screening of lung cancer allows the detection of early tumors. The objective of our study was to verify whether initial asymptomatic lung cancers, identified by high-resolution low-dose CT (LD-CT) on a high-risk population, show genetic abnormalities that could be indicative of the early events of lung carcinogenesis. We analyzed 78 tumor samples: 21 (pilot population) from heavy smokers with asymptomatic nonscreening detected early-stage lung cancers and 57 from 5203 asymptomatic heavy smoker volunteers, who underwent a LD-CT screening study. During surgical resection of the detected tumors, tissue samples were collected and short-term cultures were started for karyotype evaluation. Samples were classified according to the normal (NK) or aneuploid (AK) karyotype. The NK samples were further analyzed by the Affymetrix single-nucleotide polymorphisms (SNPs) technology. Metaphase spreads were obtained in 73.0% of the selected samples: 80.7% showed an AK. A statistically significant correlation was found between presence of vascular invasion and abnormal karyotype. A total of 10 NK samples were suitable for SNPs analysis. Subtle genomic alterations were found in eight tumors, the remaining two showing no evidence to date of chromosomal aberrations anywhere in the genome. Two common regions of amplification were identified at 5p and 8p11. Mutation analysis by direct sequencing was conducted for the K-RAS, TP53 and EGFR genes, confirming data already described for heavy smokers. We show that: (i) the majority of screening-detected tumors are aneuploid; (ii) early-stage tumors tend to harbor a less abnormal karyotype; (iii) whole genome analysis of NK tumors allows for the detection of common regions of copy number variation (such as amplifications at 5p and 8p11), highlighting genes that might be considered candidate markers of early events in lung carcinogenesis.
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Introduction
In the last 20 years, the incidence of lung cancer has significantly grown, especially when related to tobacco usage. Of the over 1 million new cases identified worldwide per year, more than 900 000 (about 90%) will result in death. The highest rates are currently observed in Europe and North America. With over 160 000 deaths from lung cancer, this disease now accounts, per annum, for about 30% of all cancer deaths in the United States alone (Jemal et al., 2008) , and there has been a 600% increase in the incidence among women, following increased prevalence of smoking, in the last 80 years (Patel et al., 2004) .
After smoking cessation, the risk of lung cancer does not drop promptly, with the result that it has become the leading cause of death among current and former smokers. Recently, some success in the controlling of tobacco consumption has been achieved in several developed countries: nevertheless, global consumption of tobacco continues to grow (Enstrom and Heath, 1999; Proctor, 2001; Jemal et al., 2008) .
One of the major difficulties in the management of lung cancer is late diagnosis, whereas the lung cancer patients who are cured are typically those with localized disease that can be surgically removed, but hardly identified because asymptomatic (Horner et al., 2009) .
It stands to reason that the development of early noninvasive screening procedures is needed (Henschke et al., 1999; Diederich et al., 2004; Humphrey et al., 2004; Mulshine and Sullivan, 2005) , these offering the unique opportunity to successfully achieve lung cancer early detection and increase survival. Amongst existing screening techniques, low-dose spiral CT (LD-CT) has been proven to be highly sensitive and specific (Veronesi et al., 2007) in detecting the disease at its initial stages (stage IA-IB, characterized by absence of lymph nodes involvement as well as absence of distant metastases).
The Continuous Observation of Smoking Subjects (COSMOS) study, recruited 5203 heavy smoker volunteers at the European Institute of Oncology, to be annually screened by LD-CT, and has identified, in 4 years, 160 lung cancer early and/or asymptomatic cases (Veronesi et al., 2007 ). This population is exceptionally interesting, because the continuous monitoring of high-risk subjects enhances the possibility of identifying and studying lung cancer in its initial stages. Thus the series of asymptomatic tumors we had detected represented a great opportunity to search for the presence of early genetic events that could plausibly illustrate which specific defects affect the tumoral genome at the early steps of tumor formation.
Conventional cytogenetics or comparative genomic hybridization studies evidenced the presence of several chromosomal alterations in lung cancers, involving the loss or gains of entire chromosome arms, such as the common losses of 3p, 6q, 8p, 9p, 9q, 13q, 17p, 18q, 19p, 21q and 22q, as well as gains of 1p, 1q, 3q, 5p, 7p, 7q, 11q and 12q, detected in non-small cell lung cancers (Mitsuuchi and Testa, 2002) . Chromosome numerical alterations (aneuploidies) have also been described. The analysis of over 300 non-small cell lung cancers cases, retrieved through the Mitelman database of chromosome aberrations in cancer (publicly available on-line at the website http://cgap.nci.nih.gov/Chromosomes/ Mitelman), clearly shows that chromosome losses dominate over gains. The most common losses detected in the analyzed cases involve loss of chromosome Y, 9 or 14, whereas supernumerary chromosomes 7, 12 or 20 represent the most frequent gains. More recently, highresolution genome-wide approaches, such as arraycomparative genomic hybridization and whole-genome single-nucleotide polymorphisms (SNPs) analysis, have been applied to the study of large collections of lung cancer patients (Tonon et al., 2005; Zhao et al., 2005; Weir et al., 2007) , in order to verify alterations also at a submicroscopic level, which could lead to a more complete characterization of the lung cancer genome. In another study, 623 human genes were searched for somatic mutations by sequencing a total of 247 Mb in 188 primary adenocarcinoma (ADK) genomes (Ding et al., 2008) . Such an effort resulted in the identification of 26 significantly mutated genes in this specific type of lung cancer. Although these results mostly identified recurrent genomic lesions, there are no studies attempting to define those abnormalities that could specifically typify the early genetic events in lung carcinogenesis. Notably, the study of aneuploid karyotypes (AKs), particularly when a high degree of abnormalities is present, would be of no help in defining one or few specific alterations and/or genetic defects, marking the initial steps of the tumorigenic processes, which could be instead emphasized by a detailed investigation of macroscopically normal tumoral genomes. We decided to address this issue by using two consecutive strategies, with the aim to (i) highlight the presence of lung cancers with a normal karyotype and (ii) extensively examine such tumors for subtle genetic alterations. Therefore, we first performed a macroscopic analysis, in order to verify the presence of tumor samples carrying evident chromosome alterations (AKs, which we did not study further, because of the high extent of genetic defects identifiable in such genomes), or of tumor samples with a normal numerical chromosome content (normal karyotypes (NKs)). Subsequently we performed a high-resolution genomic analysis exclusively on NK samples, in order to investigate for the presence of genomic alterations, possibly indicating early genetic events in lung tumorigenesis.
Our results show that the vast majority (80%) of the screening-detected tumors had an abnormal genome content (AKs); however, a restricted number of cases did carry a macroscopically normal genome (NKs), with subtle defects.
Results
A total of 78 tumor samples were collected from 57 male and 21 female patients. The mean age was 63 years. The mean pack-years was 50. High-resolution genomic analysis Among the 57 cases analyzed, 11 NK tumors were detected. One DNA sample had to be excluded, as there was no frozen tumor tissue and the quality of the DNA extracted from the correspondent paraffin-embedded sample did not match the criteria required for the HuSNPs Chip analysis (case #42 in the tables). The remaining 10 samples, along with the matched normal controls, were subjected to SNPs genotyping. Table 2 summarizes the results obtained listing all the abnormalities found as well as the genomic size of each alteration. Two cases showed a great variety of genomic alterations (group I in Table 2 ), two harbored no abnormalities (group II in Table 2 ), and six showed a limited number of alterations (not more than 2-3 in the same sample) with both focal and largescale events (group III in Table 2 ). The different typologies of alterations identified with CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping) were validated by means of real-time quantitative PCR (RQ-PCR), in selected regions, as described in Materials and methods. Cases 3 to 8, characterized by a reduced number of alterations, are particularly interesting. Indeed, the low number of genomic defects, concomitantly present in each case, might indicate events marking the early steps of the tumorigenic transformation in each one of these samples. In addition, by comparing the anomalies found amongst all the different samples, we noted that three appeared more than once (bolded in Table 2 ): these consist of two amplifications (one large-scale and one focal) and one deletion (loss of heterozygosity (LOH), large-scale). We decided to focus on the two common amplifications, involving the chromosomes 5 and 8. The amplification at 5p involved the entire short arm and was detected in 3/12 cases, two in association with several other abnormalities and one together with a second amplification on chromosome 16q. The second common event, instead, involved a smaller genomic region (focal event), of about 1 Mb at 8p11. This defect was found in two cases, either in association with a large number of additional anomalies, or together with the amplification of 22q only. We performed genomic RQ-PCR with 8p11-specific primers on a total of 44 additional lung tumor samples and detected 4/44 cases carrying the amplification. Moreover, RQ-PCR walking on such cases, using suitable primer pairs covering this region (see Figure 1 ), allowed to precisely defining the extent of the amplified area. As shown in Figure 1 , representing the two most significant samples, the minimal amplified region at 8p11 extended for about 1 Mb and included the ADAM18, ADAM2, INDO, INDOL1 and ZMAT4 gene loci. Interestingly, in 5/44 cases genomic RQ-PCR revealed the presence of 8p11 LOH, involving also the 1 Mb above defined area. Whole-genome analysis of early lung cancers E Belloni et al
We also extended our analysis by searching for the presence of sequence variations in genes that have been found frequently mutated in lung cancer, namely K-RAS, TP53 and EGFR. The full coding sequence, complete of intron-exon junctions, of the K-RAS and TP53 genes, was analyzed, whereas only exons 18-21 of EGFR were SNPs analysis was performed according to the standard Affymetrix protocol. Briefly, genomic DNA was quantified by NanoDrop spectrophotometer and run on agarose gel to exclude sample degradation. 250 ng of genomic DNA was digested with either XbaI or HindIII restriction enzymes, depending on the GeneChip Mapping array to be applied too. Adapter sequences were ligated to digested DNA fragments and the ligated fragments were amplified by PCR under limiting conditions. PCR parameters were designed to favor the amplification of DNA fragments 250-1000 bp in size, achieving an up to 10-folds reduction in genome complexity. PCR products were then purified, fragmented and terminally labeled with biotin. The hybridization cocktail was then applied to the specific GeneChip Mapping array and hybridization took place in a rotisserie oven for 16 h at 48 1C and 60 r.p.m. speed. Mapping arrays were washed and stained using the Fluidic Station 450 and scanned using the GeneChip scanner 3000 7G according to manufacturer's specifications. For the sequence analysis, each forward and reverse primer was designed in such a way to include also a 5 0 universal tail, consisting of a PE-21 and a M13rev sequence, respectively. This strategy allows to sequencing all the different PCR fragments with only two sequencing primers. Primers were also designed with a similar Tm, so that all the different regions could be amplified at the same time in isothermal conditions. Following the PCR reactions, products were controlled on 1% agarose gel, quantified and purified, by removing free PCR primers and dNTPs. An appropriate amount of each amplicon was used in the sequencing reactions. Each region was covered 2 Â, using both PE-21 and M13rev primers. The sequencing reactions were set up using BigDye v3.1 chemistry from Applyed Biosystems (Sanger's method). Purification from unincorporated terminators was performed before reactions loading.
Whole-genome analysis of early lung cancers E Belloni et al taken into consideration, given the fact that most of the lung cancer associated mutations described to date lie within this portion of the gene. We decided to perform this part of the study on all the NK cases (11 in total), and on 20 aneuploid tumors (chosen as representative of our population). The results are summarized in Tables 2  and 3 and reported in Supplementary Table 2 , 3, and 4.
Discussion
The presence of genomic alterations in tumor DNA is a recognized hallmark of human cancers. Although it is accepted that other events, for example, those epigenetically acting on and affecting either chromatin structure or transcription, may be active players in tumor growth (Shames et al., 2006; Esteller, 2008; Ebi et al., 2009) , the complete characterization of each cancer genome remains a key step towards a definitive understanding of the tumorigenic process. At the same time, the identification of those defects defining the early steps of cancer development will result in a better knowledge of the very initial molecular alterations triggering cancer onset. One major effect of such an accomplishment would be the possibility of setting up new diagnostic tools, which could allow detection of the disease even in the asymptomatic stages. Prevention and treatment will be certainly improved by a better understanding of the molecular origins and evolution of the disease. This is of particular relevance for lung cancer, characterized by a very low survival rate, because of late diagnosis and lack of successful criteria for early disease detection. Therefore, the COSMOS screening, which is based on the continuous observation of a high-risk population, represented an extraordinary resource for the analysis of the genomic status of asymptomatic lung cancers at various stages of progression (early to more advanced stages Beroukhim et al., 2010) , in order to assess the presence of genetic defects (genomic amplifications and/or deletions). Nevertheless, these works did not take into consideration the possibility of distinguishing between highly rearranged (AK) and apparently normal genomes (NK). This is an important distinction, because it can provide an indication of the putative genetic events marking the early steps of lung tumorigenesis. Therefore, we firstly focused on the assessment of the genomic status, by analyzing metaphase spreads from the surgical-resected tumor tissue samples (macroscopic analysis). We found that the vast majority of the samples, despite being frequently in the early stages, carried an aneuploid karyotype, indicating that a high degree of genomic abnormalities can be evidenced even in screening-detected asymptomatic tumors. Our data did not evidence a specific and statistically significant association between presence of aneuploidy and several of the clinical and pathological parameters analyzed. A major criticism against high-risk population screening-based protocols for lung cancer detection is an overdiagnosis bias, according to which, CT-detected cancers include a significant percentage of relatively slow-growing, indolent cancers, whose apparent longer survival is likely due to the non-aggressive nature of such cancers, more than to a real benefit of the screening itself. However, as CT-detected cancers can carry a high degree of aneuploidy, commonly evidencing the presence of genomic instability, which is a distinctive tumor hallmark, we think that our results, although need to be confirmed in a larger cohort, contribute to support the Additional data come in support of this conclusion. Aneuploidy was detected in the majority of grade 1 tumors, which are considered less aggressive. Moreover, the proportion of AKs in tumors characterized by a BACs (usually a sign of less aggressive behavior) resembles that identified in tumors not showing this feature, indicating that also less aggressive tumors might harbor a very unstable genome. In this sense, our data confirm recently reported conclusions underlining that screening-detected stage I lung cancers share most of the pathological features and gene expression profiles (Bianchi et al., 2004) of fully malignant tumors.
At the same time, we found a statistically significant correlation between AK and vascular invasion, thus a normal karyotype may indicate a lower degree of metastatic potentiality. Interestingly, absence of macroscopic genomic alterations was more common, even though not statistically significant, among stage I and smaller (o15 mm) tumors, as well as those not showing necrosis. In addition, none of the lymph node-positive tumors carried an AK. Nevertheless, very small lesions can also present a completely abnormal genome. Indeed, our results confirm that among LD-CT-detected tumors, even at early stages, an abnormal chromosome content is a common feature, further indicating the importance of distinguishing between AK and NK tumors. Overall, our screening approach can greatly enhance the possibility to identify lung cancers with a macroscopically normal genome, as demonstrated by the 23.2% (10/43) NK tumors detected within the COSMOS study, versus the 7.1% (1/14) among the pilot non-screening collection. The difference between AK and NK lung tumors, if confirmed on larger cohorts, might translate in evaluations on the tumor prognosis. However, at present, it is not possible to correlate karyotypes to prognostic outcomes because of both the limited followup data and the small number of lung cancer deaths among our patients. Surprisingly, we could show a correlation at the limit of statistical significativity between the number of pack-years (more than 60) and the presence of a NK. The clinical significance of this correlation, if any, is not clear and needs further confirmation.
The identification of early stage lung tumor samples without macroscopic genomic alterations (NK samples) prompted us to conduct a whole-genome analysis on such samples, in order to search for the presence of subtle genomic alterations, which could be a sign of early stages of lung tumorigenesis (microscopic analysis). A total of 11 NK tumor samples were found in our population, and 10 were eligible for whole-genome analysis, resulting in the genomic characterization summarized in Table 2 . We included in our analysis the search for mutations in three genes among those mostly involved in lung cancer (Ding et al., 2008) . On the basis of the results of our analysis we separated our NK samples in three groups: (I) two tumor samples with several genomic alterations. The genome of these samples presented a high number of copy-number alterations, in various chromosome regions, and from a genetic point of view can be considered, similarly to AK samples, less relevant, because they do not consent the identification of early events. (II) Two tumor samples with no evidence of subtle genomic alterations (although it is possible that a similar analysis at a higher level of resolution, for example, using the Affymetrix 250K array (Affymetrix, Santa Clara, CA, USA), could identify sub-microscopic genomic abnormalities, eluded by this study). As for point mutations in genes specifically associated to lung cancer (Ding et al., 2008) , we could not detect any in the three selected genes we analyzed; nevertheless, we cannot exclude the presence of sequence alterations in other genes, not screened in this study. (III) Six samples with a limited number of genomic abnormalities. These are particularly interesting because they allowed the identification of few defects that may characterize the genome of early-stage lung cancers. Interestingly, five of these six cases are stage I (either A or B) non-small cell lung cancers: only one sample is a multifocal, indent stage IV carcinoid, harboring the deletion of one chromosome X (ÀX), whereas the other five cases show copy-number alterations involving specific intra-chromosomal regions. Three of these also carry a K-RAS mutation (G12C in two and G13C in one). This is not surprising, as mutations in this gene have already been described as early events in lung carcinogenesis (Herbst et al., 2008) . We can then suppose that amplifications at 1q21.1-23.3, 3q26.1-26.2, 5p15.32-cent, 8p11, 12p11.1-12.3, 16q12.1-21, 18p, 22q, Xp11.3-11.23 and LOH at 8ptel-p11 might all represent early genetic events in nonsmall cell lung cancers onset. In particular, amplifications at 5p and 8p11, together with LOH at 8p, were detected in more than one of the analyzed cases. Considering the known difficulties in assessing the presence of LOH, due to the unavoidable presence of genomic DNA from normal cells in tumor tissue samples, we concentrated our analysis on the regions of amplification. We identified three large scale and six focal events. Among them, those affecting 1q21.2-23.3, 5p15.32-cent, 8p11 and 12p11.1-12.3 have already been previously described (Tonon et al., 2005; Zhao et al., 2005; Weir et al., 2007; Beroukhim et al., 2010) : the remaining five have never been involved in lung cancer whole-genome studies. Interestingly, as already reported, the amplifications of 1q21.2-23.3 and 12p11.1-12.3 encompass the ARNT and K-RAS genes, respectively. Although the role of KRAS in lung cancer has been largely known and described (reviewed in Herbst et al., 2008) , ARNT (aryl hydrocarbon nuclear translocator) is known to interact with AHR (aryl hydrocarbon receptor), giving rise to a transcriptional regulatory heterodimer implicated in the carcinogenic action of cigarette smoke (Puppala et al., 2007) . Recently, it was reported to be involved, albeit indirectly through the aryl hydrocarbon receptor repressor (AHRR), in multiple human cancers, including lung (Zudaire et al., 2008) , as well as associated to acute myeloid leukemia through the TEL-ARNT fusion protein (Nguyen-Khac et al., 2006) .
As for the two amplified regions of chromosomes 5 and 8, these have been detected in more than one of our NK samples (amp5p in three and amp8p11 in two cases). 5p amplification has already been described in previous studies as a quite common event in lung cancers. More specifically, in the study performed by Weir et al. (2007) , who characterized the lung ADK genome in over 500 samples, the copy-number gain of chromosome 5p is described as the most common genomic alteration, found in the 60% of total samples. Moreover, the data obtained in that study on focal copy-number variations, shows that a 1 Mb region at 5p also containing the TERT gene (along with other additional nine genes) is found amplified in eight of the studied samples, strongly indicating that a gene important for lung carcinogenesis might reside in this specific region. Although our results are consistent with the definition of this amplification as a common event in lung cancer, they also suggest that this alteration might have a role in the early steps of the tumorigenic process, as is found in NK lung cancers and, at least in one case, together with only one additional genomic abnormality (16q12.1-21 amplification). Similarly, the 8p11 amplification we detected has been described in previous studies. In the study by Tonon et al. (2005) , the amplified area was restricted by genomic RQ-PCR to a region including the WHSC1L1 and LETM2 genes. A second study, by Zhao et al. (2005) , defined an amplified area of about 1 Mb, located just telomerically to that previously identified. Our fine mapping results indicate that the common amplicon among our cases partially overlaps that reported by Zhao et al. (2005) , starting from its terminal portion and further extending for about 1 Mb. Five genes have been mapped to this area: ADAM18, ADAM2, INDO, INDOL1 and ZMAT4. No data are available on the possible involvement in cancer for ADAM18 and ADAM2, two members of the ADAM (a disintegrin and metalloprotease domain) family, as well as ZMAT4 (a gene encoding a zinc-finger protein). More is known about INDO and INDOL1, which encode two proteins involved in tryptophan catabolism. Several studies, especially regarding INDO, have demonstrated their role in inducing immune tolerance, leading to the hypothesis that these proteins might trigger a mechanism of immune tolerance against tumors (Uyttenhove et al., 2003; Metz et al., 2007) . INDO expression has been described in several tumors and studies in animal models evidenced that tumors expressing INDO resist immune rejection and expand leading to death (Uyttenhove et al., 2003) . Besides, the growth of subcutaneously induced tumors in mice was significantly slowed down, although not prevented, by treatment with 1-methyl-Ltryptophan, a competitive inhibitor of INDO (Uyttenhove et al., 2003) . Further studies are needed to investigate a possible involvement of these genes in lung carcinogenesis. Nevertheless, our data account for the hypothesis that also this common genomic alteration, although less frequent than the 5p amplification, might represent an important event among those marking the early steps of lung tumor development.
Concerning the mutation analysis we performed, assaying the K-RAS, TP53 and EGFR genes, our results are in agreement with what already reported (reviewed in Herbst et al., 2008) : (i) K-RAS mutations are more frequently found in lung cancers arising in smokers, and all of our patients are heavy present or former smokers; (ii) none of the patients we analyzed, either NK or AK, carry EGFR mutations, which, in fact, are more frequently found in non-smokers. As a matter of fact, EGFR mutations represent the first specific genetic alteration associated with never-smokers, and increasing smoke exposure negatively correlates with sequence variations within this gene; (Sun et al., 2007) (iii) we could detect TP53 mutations, one of the most common changes in human tumor cells, commonly seen in both smokers and never-smokers.
Interestingly, the frequency of sequence abnormalities in the three genes we examined is higher in AK than NK samples (Table 3) , as one would expect in a more unstable genome and as also described by Ding et al. (2008) , showing that gene mutations recurred more frequently in association with copy-number variations in the genomes they analyzed.
Recently, Beroukhim et al. (2010) conducted the largest analysis of high-resolution copy-number evaluation in 26 different cancer types (over 3000 cancer specimens). This study identified 357 regions of focal copy-number alterations (either amplifications or deletions), including some events common to several cancer types (158) and others specific to individual cancer subgroups (199) . An emerging challenge for the scientific community would be the definition of a catalog of cancer-related copy-number alterations, both common to all major cancer types and typical of specific categories. The final expected result will be that of identifying specific cancer-related genes, which could become targets for therapeutic interventions. This work already provided two examples with the MCL1 and BCL2L1 genes, which appear to be amplification targets. One requisite to fulfill this goal resides in the availability of data collected on the highest possible number of cancer samples. Similar studies and others specifically related to single tumor types, as the one we are presenting, can contribute to the gathering of all the information required to associate specific genetic events to the onset of cancer (common as well as type-specific defects).
In summary, in our work, we highlight the importance of studying a screened high-risk population to investigate if tumors with a normal chromosome complement might harbor a limited number of subtle genetic defects. Such events, when arising in tumors at early stages, can provide new indications on the putative initial genetic modifications, which mark the early steps of tumor formation in the lung tissue, and thus offer new opportunities for research directions and improved diagnosis and prognosis.
Materials and methods
Patients 5203 asymptomatic heavy smokers or former smokers volunteers, with a smoking history of more than 20 packyears and age X50 years, were enrolled in the COSMOS study (a spiral low-dose CT scan screening approach) started at the European Institute of Oncology in 2004 (Veronesi et al., 2007 . At the end of the second year, among 89 screeningidentified patients with lung cancers, 57 cases with clinical localized lung malignancy were evaluated for the present analysis. These, together with 21 other asymptomatic patients (pilot population), carrying non-screening-detected lung cancers, harboring similar characteristics to the screened population (asymptomatic, smokers, older than 50 years, with an occasionally detected localized cancer), constituted our study population (78 cases). We excluded cases submitted to preoperative or definitive chemotherapy or with no adequate tissue availability for the genomic analysis.
Lung tumor samples
At the time of surgical resection, a portion of the tumoral tissue was collected, snap-frozen and stored at À80 1C for subsequent evaluation and DNA extraction. Tumor cellularity was determined by analyzing hematoxylin-eosin stained sections of the frozen samples. The evaluation was carried out by a pathologist of the Molecular Pathology Unit, at the IFOM-IEO Campus. Only NK samples with a tumor cellularity of at least 70% were used for the high-resolution genomic analysis: this allowed us to limit normal cells contamination of the tumor genomes. DNA extraction was performed on 10-15 4 mm sections, cut from the frozen tumor samples, using the GenomicPrep Cells and Tissue DNA isolation kit (GE-Healthcare, Chalfont St Giles, UK).
Patients' and tumors' characteristics are listed in Supplementary Table 1 .
Normal controls
Peripheral blood samples from each patient were collected before surgical resection, as a source of tumor-matched normal DNA, obtained according to standard methodologies (Miller et al., 1988) .
Ploidy evaluation
Following diagnosis, during surgical resection, fresh tumor tissue samples were collected to start short-term cultures. Samples were mechanically dissociated and cultures were started for 24, 48 or 72 h (depending on the sample size) in Ham's F10 medium with 10% fetal bovine serum, NA, Pen/ Strep and Glutamine. Karyomax Colcemid Solution (Invitrogen, Carlsbad, CA, USA) was then added and left for 2 h at 37 1C. Cells were centrifuged and resuspended in 0,075 M KCl for 30 min at 37 1C and then fixed with a 3:1 Methanol:Acetic Acid solution. The resulting nuclei suspension was used to prepare slides for metaphase spreads evaluation. By simply counting metaphase chromosomes, diploidy (46 chromosomes) or aneuploidy (more or less than 46 chromosomes) was established for each sample. Importantly, as the analyzed metaphase spreads could also belong to normal cells, always present in the tumor tissue samples, although in variable amounts, we examined at least 10 normal metaphase spreads for each given genome, before classifying it as normal.
SNPs array experiments
In all those tumors showing a normal genomic content, SNPs genotyping was performed with the Affymetrix GeneChip Human Mapping 100K arrays set (Mapping 50K Hind 240 Array or Mapping 50K Xba 240 Array) according to the manufacturer's instructions. For details, see the legend to Table 2 . The tumor DNA content was compared with that of a normal control (see below). Coverage of one SNP every 60Kb is guaranteed, leading to the identification of genomic alterations non-detectable with the conventional cytogenetic analysis. Array data have been posted at the ArrayExpress Archive database and are publicly available (www.ebi.ac.uk/ arrayexpress; ArrayExpress accession: E-MEXP-2450).
SNPs data analysis
Data were analyzed with the CNAGv3.0 software package (Nannya et al., 2005) , which implemented an algorithm for copy number detection and is freely available to academic users. Paired analysis was carried out for each tumor-normal control matched pair, in order to identify all the possible abnormalities that CNAG is able to define: LOH, amplification and uniparental disomy. Unpaired analysis was also performed for each tumor sample, in order to avoid missing possible germline DNA alterations (Reference Genomic DNA: Affymetrix internal normal genomic control, 103 Human genomic DNA control).
RQ-PCR
Sybr green. SNPs results were validated by RQ-PCR on the tumor versus normal genomic DNA of each sample. RQ-PCR was performed using the SYBR Green technology on an ABI PRISM 7700 sequence detection system (PE Applied Biosystems, Foster City, CA, USA). PCR reactions were prepared in a final volume of 25 ml (1 Â SYBR Green PCR master mix; 5 ng DNA). Results were normalized to a control genomic sequence, corresponding either to the MYB or the HOXa9 genes. Each SNP genomic region versus MYB or HOXa9 amplicons (test/normalizer) ratio for the studied cases was also normalized to the same ratio concomitantly measured in a total human DNA control sample (Total Human DNA, Roche Applied Science, Indianapolis, IN, USA), as a calibrator. This same approach was used for RQ-PCR walking experiments, defining the focal region of amplification at 8p11 (Figure 1) . Sequences of primer pairs are available upon request.
TaqMan. Real-time PCR to determine the 8p11 amplification frequency was carried out on the ABI/Prism 7900 HT Sequence Detector System (Applied Biosystems), using a pre-PCR step of 10 min at 95 1C, followed by 40 cycles of 15 s at 95 1C and 60 s at 60 1C. DNA (5 ng) was amplified (in triplicate) in a reaction volume of 15 ml containing the following reagents: 7.5 ml of TaqMan PCR Mastermix 2 Â No UNG (Applied Biosystems), 0.75 ml of TaqMan Gene expression assay 20 Â (Applied Biosystems). Samples were amplified with gene-specific primers and normalized to a control genomic sequence, corresponding to the HOXa9 gene (assay sequences available upon request). Our analysis was extended to a total of 44 cases, including advanced lung tumor samples, not identified through the COSMOS screening.
Direct sequencing analysis
The regions of interest were amplified using exon-specific primers, covering the coding sequence from the start to the stop codon (except for the EGFR gene). Each primer pair was designed on intronic regions, in order to include the splicing junctions. For details, see the caption to Table 2 . The sequencing reactions were loaded into the capillaries of the 3730xl sequencer (Applyed Biosystems) and analyzed with the
